UNSPSC 51283307: Tedizolid

A type of antibacterial drug indicated for treatment of acute bacterial skin and skin structure infections by susceptible bacteria.

UNSPSC 51283307 Tedizolid is a Commodity code nominally identifying a specific antibiotic pharmaceutical, yet recent state and local procurement activity under this code does not align with tedizolid itself; instead, the category appears to be used broadly for pharmaceutical and medical supply procurement across varying product categories and health-sector applications. The work being solicited encompasses naloxone and drug deactivation systems for community health programs, direct-to-manufacturer pharmacy prescription programs, emergency medical and first aid supplies for fire departments, and generic multi-source pharmaceuticals and over-the-counter products for state and local health facilities. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), municipal procurement offices (City of Tampa), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). Issuing bodies range from single counties and cities to multi-state cooperative vehicles that serve participating state and local government facilities across multiple jurisdictions.

Geographic activity centers on Florida, Texas, and Minnesota, with the MMCAP RFP extending procurement scope to Oregon and other participating states. Recent representative solicitations include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (due July 26, 2023), the City of Tampa's sealed-bid procurement for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division with an estimated contract amount of $700,000.00 (due March 13, 2026), and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities nationwide (due March 26, 2026). The Texas HHS Commission also issued an RFI in April 2026 exploring vendor capacity for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. Procurement mechanisms vary—ITBs and sealed bids dominate when procuring emergency supplies and standardized pharmaceuticals, while RFPs and RFIs characterize larger program-design initiatives. The Tampa procurement includes a sheltered-market set-aside for certified Small Local Business Enterprises with a 5 percent bid discount, while MMCAP's RFP specifies 3 percent administrative-fee structures and performance penalties for non-compliance.